GlassScriptPhysician profile
Karen H Fu
NPI 1528007861
$2,268.25
in general payments reported to CMS, 2019-2025
23 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $174 · 2021: $88.61 · 2022: $403 · 2023: $325 · 2024: $349 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $545.19 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $400.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $185.44 | 2019-2024 | |
| Amgen INC. | $153.97 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $130.28 | 2019-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $130.19 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $88.11 | 2022-2025 | |
| Exact Sciences Corporation | $70.75 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $65.12 | 2019 | |
| Astellas Pharma US INC | $62.57 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $59.17 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Allergan, INC. | $53.65 | 2019-2020 | |
| Edwards Lifesciences Corporation | $45.50 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bayer Healthcare Pharmaceuticals INC. | $45.02 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.68 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $40.51 | 2022 | |
| Currax Pharmaceuticals LLC | $28.52 | 2025 | Contrave |
| Sanofi-Aventis U.S. LLC | $27.56 | 2025 | |
| Sanofi Pasteur INC. | $25.00 | 2019 | |
| Antares Pharma, INC. | $21.25 | 2019 | |
| Medtronic USA, INC. | $19.06 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.99 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.